Skip to main content
Signal8
Launch Terminal

Vir Biotechnology, Inc. (VIR)

Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc.

NASDAQ:VIRHealthcare
-3.83%$11.30
AH$11.66+3.19%vs close
Mkt Cap$1.91B
Float132.16M
O/S169.22M
Vol
$ Vol
RVOL
Inst Own86.7%
Earnings
Dilution
Vir Biotechnology, Inc. logoNASDAQ:VIR$11.30-3.83%
Phase Distribution
22 lead-sponsored trials·6 active·12 completed
Phase 18
Phase 1/23
Phase 26
Phase 2/31
Phase 33
Not applicable1
(13 more as collaborator)
Status Overview
Recruiting2
Active, not recruiting4
Completed12
Stopped3
Expanded access1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Terminated

    Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

    sotrovimab, sotrovimab

    Covid19

    Enrollment
    1,065
    Start
    Jun 2021
    Primary Completion
    Jul 2022
    Completion
    Mar 2023
    NCT04913675
  • Phase 3
    Active, not recruiting

    A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

    Tobevibart, Elebsiran

    Viral Hepatitis

    Enrollment
    124
    Start
    Mar 2025
    Primary Completion
    Dec 2026est.
    Completion
    May 2031est.
    NCT06903338
  • Phase 3
    Active, not recruiting

    A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

    Tobevibart, Elebsiran

    Viral Hepatitis

    Enrollment
    150
    Start
    Jul 2025
    Primary Completion
    Dec 2026est.
    Completion
    Jul 2031est.
    NCT07128550
  • Phase 2/3
    Completed

    VIR-7831 for the Early Treatment of COVID-19 in Outpatients

    VIR-7831 (sotrovimab), Placebo

    Covid19

    Enrollment
    1,057
    Start
    Aug 2020
    Primary Completion
    Apr 2021
    Completion
    Sep 2021
    NCT04545060
  • Phase 2
    Completed

    Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

    VIR-2218, pegylated interferon-alfa 2a

    Chronic Hepatitis B

    Enrollment
    84
    Start
    Jul 2020
    Primary Completion
    Mar 2024
    Completion
    Mar 2024
    NCT04412863
  • Phase 2
    Completed

    Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19

    Sotrovimab (Gen1), Sotrovimab (Gen2)

    Covid19

    Enrollment
    354
    Start
    Feb 2021
    Primary Completion
    Aug 2021
    Completion
    Apr 2022
    NCT04779879
  • Phase 2
    Completed

    Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

    VIR-2218, VIR-3434

    Hepatitis B, Chronic

    Enrollment
    244
    Start
    Jul 2021
    Primary Completion
    Mar 2026
    Completion
    Mar 2026
    NCT04856085
  • Phase 2
    Active, not recruiting

    SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

    VIR-2218, VIR-3434

    Hepatitis D, Chronic

    Enrollment
    95
    Start
    Sep 2022
    Primary Completion
    Nov 2031est.
    Completion
    May 2032est.
    NCT05461170
  • Phase 2
    Terminated

    A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

    VIR-2482 (450 mg), VIR-2482 (1200 mg)

    Influenza A

    Enrollment
    2,977
    Start
    Oct 2022
    Primary Completion
    May 2023
    Completion
    Aug 2023
    NCT05567783
  • Phase 2
    Active, not recruiting

    A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

    Tobevibart, Elebsiran

    Viral Hepatitis

    Enrollment
    100
    Start
    Aug 2025
    Primary Completion
    Nov 2026est.
    Completion
    Jul 2030est.
    NCT07142811
  • Phase 1/2
    Completed

    Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B

    VIR-2218, Placebo

    Chronic Hepatitis B

    Enrollment
    82
    Start
    Nov 2018
    Primary Completion
    Sep 2020
    Completion
    Sep 2020
    NCT03672188
  • Phase 1/2
    Recruiting

    To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

    VIR-5818, pembrolizumab

    Locally Advanced or Metastatic HER2-Expressing Cancers

    Enrollment
    645
    Start
    Apr 2022
    Primary Completion
    Apr 2028est.
    Completion
    Apr 2028est.
    NCT05356741
  • Phase 1/2
    Completed

    A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

    VIR-3434, VIR-2218

    Hepatitis B, Chronic

    Enrollment
    33
    Start
    May 2023
    Primary Completion
    Oct 2024
    Completion
    Aug 2025
    NCT05612581
  • Phase 1
    Completed

    Study of VIR-2482 in Healthy Volunteers

    VIR-2482, Placebo

    Influenza A

    Enrollment
    100
    Start
    Aug 2019
    Primary Completion
    Nov 2021
    Completion
    Nov 2021
    NCT04033406
  • Phase 1
    Completed

    Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection

    VIR-3434

    Chronic Hepatitis B

    Enrollment
    113
    Start
    May 2020
    Primary Completion
    Oct 2022
    Completion
    Nov 2022
    NCT04423393
  • Phase 1
    Completed

    VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

    VIR-1111, Placebo

    HIV I Infection

    Enrollment
    27
    Start
    Dec 2020
    Primary Completion
    Dec 2022
    Completion
    Dec 2022
    NCT04725877
  • Phase 1
    Completed

    A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

    sotrovimab, sotrovimab

    Covid19

    Enrollment
    48
    Start
    Jul 2021
    Primary Completion
    Sep 2021
    Completion
    Dec 2021
    NCT04988152
  • Phase 1
    Terminated

    Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

    sotrovimab, sotrovimab

    Covid19

    Enrollment
    316
    Start
    Mar 2022
    Primary Completion
    Apr 2023
    Completion
    Nov 2023
    NCT05280717
  • Phase 1
    Completed

    Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

    VIR-2218, VIR-3434

    Hepatic Impairment, Cirrhosis

    Enrollment
    88
    Start
    Sep 2022
    Primary Completion
    Dec 2025
    Completion
    Dec 2025
    NCT05484206
  • Phase 1
    Completed

    A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

    VIR-2218

    Renal Impairment

    Enrollment
    28
    Start
    Jun 2023
    Primary Completion
    Mar 2025
    Completion
    Apr 2025
    NCT05844228
  • Phase 1
    Recruiting

    Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

    VIR-5525, Pembrolizumab

    Solid Tumor Malignancies, EGFR Positive Solid Tumors +1

    Enrollment
    450
    Start
    Jul 2025
    Primary Completion
    Aug 2029est.
    Completion
    Aug 2029est.
    NCT06960395
  • Expanded access
    No longer available

    Sotrovimab Expanded Access Treatment Protocol (COVID-19)

    Sotrovimab

    Covid19

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT05235347
Search ClinicalTrials.gov for “Vir Biotechnology”